Orca Bio Names Bijan Nejadnik as Chief Medical Officer
Orca Bio has announced a major leadership transition as the company continues advancing toward commercialization of its high-precision cell therapy platform. The company appointed Bijan Nejadnik as its new Chief Medical Officer, while longtime clinical leader J. Scott McClellan will move into the newly established role of Chief Development Officer.
The leadership changes reflect Orca Bio’s broader strategy to strengthen its executive team as it advances late-stage clinical programs and expands development activities across a growing pipeline of next-generation therapies. The company, which focuses on precision-engineered cell therapies designed to improve outcomes in allogeneic stem cell transplantation and immune-related diseases, believes the appointments position it for its next phase of growth as a potential commercial-stage biotechnology organization.
Orca Bio has gained increasing attention in the biotechnology industry for its efforts to redefine the standard of care in hematologic malignancies and immune system disorders through highly engineered donor cell therapies. Unlike traditional allogeneic stem cell transplantation, which can involve unpredictable immune complications such as graft-versus-host disease, Orca Bio’s platform aims to precisely control the composition of transplanted immune and stem cells to improve efficacy while reducing toxicities.
The company’s lead investigational programs are designed to replace diseased blood and immune systems using carefully selected cellular components intended to improve transplant outcomes for patients with blood cancers and potentially autoimmune diseases. Orca Bio believes its precision-based approach could eventually broaden access to curative cell therapies while improving both safety and long-term clinical benefit.
The appointment of Dr. Nejadnik as Chief Medical Officer comes at a particularly important time for the company as it prepares for potential commercialization activities and continues advancing late-stage development programs.
According to Orca Bio co-founder and Chief Executive Officer Nate Fernhoff, Dr. Nejadnik brings a unique combination of scientific, clinical, and regulatory expertise that will help guide the company through a critical stage of corporate evolution.
Fernhoff stated that Nejadnik’s extensive experience managing global medical and regulatory strategies across complex biologic programs will be instrumental as Orca Bio transitions toward becoming a commercial-stage organization. He also emphasized that the company intends to build a world-class medical organization capable of supporting late-stage clinical development, regulatory interactions, physician engagement, and broader patient access initiatives.
Dr. Nejadnik joins Orca Bio from Tanabe Pharma, where he served as Chief Medical Officer and Head of Research and Development and Regulatory Affairs. Over the course of more than two decades in the biopharmaceutical industry, he has developed a reputation for leading global development programs spanning oncology, immunotherapy, biologics, and advanced cell therapies.
His professional background includes extensive experience overseeing regulatory submissions and commercialization strategies across multiple international markets. Throughout his career, Nejadnik has helped guide therapies through regulatory processes involving the U.S. Food and Drug Administration, the European Medicines Agency, and Japan’s Pharmaceuticals and Medical Devices Agency.
Industry experience spanning these major regulatory agencies is considered especially valuable for biotechnology companies seeking to commercialize innovative therapies globally, particularly in highly specialized fields such as cell and gene therapy where regulatory pathways can be complex and rapidly evolving.
In addition to his operational and regulatory leadership roles, Dr. Nejadnik has also served as a board director and senior executive advisor for several biotechnology companies. His experience has included involvement in corporate strategy development, capital formation initiatives, and merger and acquisition activities, all of which may prove increasingly important as Orca Bio expands its commercial ambitions and pipeline strategy.
The company noted that Nejadnik’s clinical oversight experience extends from early-stage research programs through late-stage pivotal clinical trials across multiple therapeutic categories. His scientific and academic background also includes previous appointments at prominent research institutions including Johns Hopkins University, Cornell University, and Stanford University.
He earned his medical degree with honors from the Catholic University of Louvain in Belgium.
Commenting on his appointment, Dr. Nejadnik said Orca Bio has already made substantial progress toward redefining the treatment landscape for allogeneic stem cell transplantation through its high-precision therapeutic platform. He stated that he looks forward to helping build on the company’s existing momentum while advancing clinical innovation and strengthening the medical infrastructure necessary to support broader patient access to its therapies.
Nejadnik also emphasized the importance of maintaining high standards of scientific rigor and clinical excellence as the company advances its development programs toward potential commercialization.
At the same time, Orca Bio announced that Dr. McClellan will transition from his current role as Chief Medical Officer into the newly created position of Chief Development Officer. In this role, he will focus on expanding the company’s research and clinical development pipeline while overseeing advancement of next-generation programs into clinical testing.
The transition allows Orca Bio to separate responsibilities associated with commercial-stage medical operations from broader pipeline development and strategic research expansion. Company leadership indicated that this organizational structure is intended to better support the company’s increasingly diversified therapeutic ambitions.
Dr. McClellan has played a major role in guiding Orca Bio’s clinical development strategy, including leadership of the company’s work on Orca-T, one of its most advanced investigational programs. His continued involvement in pipeline expansion is viewed internally as critical to maintaining scientific continuity while accelerating development of future therapeutic candidates.
Fernhoff stated that Orca Bio’s underlying platform has the potential to transform treatment across a broad range of diseases by replacing dysfunctional or diseased blood and immune systems. He added that realizing the full potential of the platform requires dedicated strategic oversight focused specifically on identifying, prioritizing, and advancing the company’s next wave of therapies.
According to Fernhoff, McClellan’s expertise and leadership will be essential in shaping a pipeline strategy capable of expanding Orca Bio’s precision cell therapy approach into additional disease settings beyond its current focus areas.
For his part, Dr. McClellan described the transition as an opportunity to focus on the next stage of the company’s scientific and clinical growth. He noted that leading clinical development efforts for Orca-T had been a privilege and expressed enthusiasm about dedicating his efforts toward accelerating broader pipeline development initiatives.
McClellan also stated that he looks forward to collaborating closely with Dr. Nejadnik and the rest of the leadership team as the company continues exploring the full potential of its high-precision platform for treating blood cancers and autoimmune diseases.
The leadership changes come during a period of rapid growth and increasing competition within the cell therapy industry. Advances in stem cell engineering, immune modulation, and precision manufacturing technologies are transforming the development landscape for hematologic cancers and autoimmune conditions.
Many biotechnology companies are now pursuing strategies aimed at improving the safety, consistency, and accessibility of allogeneic cell therapies. Traditional stem cell transplantation can offer curative potential for certain blood cancers, but the procedure remains associated with substantial risks, including graft-versus-host disease, infections, relapse, and treatment-related mortality.
Orca Bio’s approach attempts to address these challenges through controlled engineering of donor graft compositions, with the goal of improving immune reconstitution while minimizing harmful inflammatory responses. If successful, such strategies could potentially expand the number of patients eligible for curative transplantation approaches while improving long-term outcomes.
As Orca Bio continues progressing toward potential commercialization and pipeline expansion, the addition of a globally experienced medical executive such as Dr. Nejadnik, combined with McClellan’s ongoing focus on research and development strategy, signals the company’s intention to strengthen both its operational capabilities and long-term innovation engine.
With late-stage clinical programs advancing and broader applications for precision cell therapy continuing to emerge, Orca Bio appears increasingly focused on establishing itself as a significant player in the evolving field of engineered cellular medicine.
About Orca Bio
Orca Bio is a late-stage biotechnology company developing high-precision cell therapies for the treatment of blood cancer and autoimmune diseases. The company’s manufacturing platform uses single-cell precision to create proprietary, uniquely defined products designed to replace a patient’s diseased blood and immune system with a healthy one. At Orca Bio, we are on a mission to redefine what’s possible for patients by transforming the field of curative allogeneic cell therapy. For more information, visit www.orcabio.com.
